Loading...
Market
Impact on Asahi Kasei's stock price post-Calliditas acquisition announcement
5
Asahi Kasei•Swedish•Calliditas Therapeutics•American Depositary Share•ADS•Calliditas•Tarpeyo•SofinnovaVC•Amolyt Pharma•CLI LimFlow
Resolution / Starting Odds
Increase over 10% • 33%
Decrease • 33%
Little to no change • 34%
Stock market data and financial news outlets
Story
Asahi Kasei to Acquire Calliditas Therapeutics for $1.1 Billion in SEK 416 per ADS Deal
May 28, 2024, 09:19 AM
Japanese conglomerate Asahi Kasei has announced its intention to acquire Swedish drugmaker Calliditas Therapeutics for approximately $1.1 billion. The deal, which includes an offer of SEK 416 or about USD $39.37 in cash per American Depositary Share (ADS), aims to bolster Asahi Kasei's pharmaceutical business. Calliditas, known for its IgA nephropathy therapy Tarpeyo, will be acquired for $1.05 billion in cash. The acquisition price is also noted as SEK 208 per share or 1.2 billion dollars. This acquisition marks the third successful exit for SofinnovaVC in the last six months, following the exits of Amolyt Pharma and CLI LimFlow.
View original story
Similar markets
Stock price up more than 10% • 25%
Stock price up 5-10% • 25%
Stock price unchanged or down • 25%
Stock price down more than 5% • 25%
Highly successful integration • 25%
Moderately successful integration • 25%
Integration with issues • 25%
Integration fails • 25%
Increase over 10% • 33%
Increase 5-10% • 33%
Less than 5% increase or decrease • 34%
Increase • 33%
No Significant Change • 34%
Decrease • 33%
Increase by more than 10% • 33%
Increase by less than 10% • 33%
Decrease • 34%
Significant growth in revenue • 25%
Moderate growth in revenue • 25%
Revenue remains stable • 25%
Revenue declines • 25%
Significant increase in Alphabet's stock price • 33%
Little to no change in Alphabet's stock price • 33%
Decrease in Alphabet's stock price • 33%
Increase by more than 5% • 33%
Decrease by more than 5% • 33%
Change less than 5% • 34%
Increase more than 10% • 25%
Increase 5-10% • 25%
Decrease • 25%
No significant change (±5%) • 25%
Stock price increases significantly • 33%
Stock price remains stable • 34%
Stock price decreases • 33%